These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1349014)
1. Increased oncogenic potential of ErbB is associated with the loss of a COOH-terminal domain serine phosphorylation site. Theroux SJ; Taglienti-Sian C; Nair N; Countaway JL; Robinson HL; Davis RJ J Biol Chem; 1992 Apr; 267(12):7967-70. PubMed ID: 1349014 [TBL] [Abstract][Full Text] [Related]
2. Signal transduction by the epidermal growth factor receptor is attenuated by a COOH-terminal domain serine phosphorylation site. Theroux SJ; Latour DA; Stanley K; Raden DL; Davis RJ J Biol Chem; 1992 Aug; 267(23):16620-6. PubMed ID: 1379601 [TBL] [Abstract][Full Text] [Related]
3. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential. Shu HK; Pelley RJ; Kung HJ Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9103-7. PubMed ID: 1979168 [TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine kinase activities of the epidermal growth factor receptor and ErbB proteins: correlation of oncogenic activation with altered kinetics. Nair N; Davis RJ; Robinson HL Mol Cell Biol; 1992 May; 12(5):2010-6. PubMed ID: 1314948 [TBL] [Abstract][Full Text] [Related]
5. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases. Guy PM; Carraway KL; Cerione RA J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772 [TBL] [Abstract][Full Text] [Related]
6. Disease tropism of c-erbB: effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation. Pelley RJ; Maihle NJ; Boerkoel C; Shu HK; Carter TH; Moscovici C; Kung HJ Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7164-8. PubMed ID: 2550929 [TBL] [Abstract][Full Text] [Related]
7. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor. Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456 [TBL] [Abstract][Full Text] [Related]
8. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Akiyama T; Matsuda S; Namba Y; Saito T; Toyoshima K; Yamamoto T Mol Cell Biol; 1991 Feb; 11(2):833-42. PubMed ID: 1671296 [TBL] [Abstract][Full Text] [Related]
9. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling. Huang Y; Kim SO; Jiang J; Frank SJ J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595 [TBL] [Abstract][Full Text] [Related]
10. Dissecting the activating mutations in v-erbB of avian erythroblastosis virus strain R. Shu HK; Pelley RJ; Kung HJ J Virol; 1991 Nov; 65(11):6173-80. PubMed ID: 1681117 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889 [TBL] [Abstract][Full Text] [Related]
13. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Segatto O; King CR; Pierce JH; Di Fiore PP; Aaronson SA Mol Cell Biol; 1988 Dec; 8(12):5570-4. PubMed ID: 2907606 [TBL] [Abstract][Full Text] [Related]
14. NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant. Messerle K; Schlegel J; Hynes NE; Groner B Mol Cell Endocrinol; 1994 Oct; 105(1):1-10. PubMed ID: 7821711 [TBL] [Abstract][Full Text] [Related]
15. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product. Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. Stern DF; Kamps MP; Cao H Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744 [TBL] [Abstract][Full Text] [Related]
18. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity. Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090 [TBL] [Abstract][Full Text] [Related]